Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium Read More

MammaPrint is the only FDA-cleared gene expression test to identify Read More

Demonstrates the ongoing impact of its 10,000-patient FLEX trial to Read More

The LESS study will evaluate reduced endocrine therapy for HR+/HER2- Read More

Data show MammaPrint® is the first and most comprehensive FDA-cleared test Read More

Data demonstrate Research Use Only ImPrint test’s ability to identify Read More

Company to present multiple recent Registry sub-studies driving cancer care Read More

Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More

Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More

January 27, 2022 By Leo O’Connor NEW YORK ─ As part Read More